# HEALEY ALS Platform Trial - Regimen B Verdiperstat

> **NCT04436510** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merit E. Cudkowicz, MD** · enrollment: 167 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Matching Placebo
- **DRUG:** Verdiperstat

## Key facts

- **NCT ID:** NCT04436510
- **Lead sponsor:** Merit E. Cudkowicz, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-28
- **Primary completion:** 2022-04-13
- **Final completion:** 2022-12-06
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2023-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04436510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04436510, "HEALEY ALS Platform Trial - Regimen B Verdiperstat". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04436510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*